source
- Novartis and BMS pause autoimmune CAR-T trials after patient deaths and safety concernsNovartis, Bristol Myers Squibb and several other biotech firms have recently encountered setbacks while developing therapies for autoimmune diseases. Some programs have been completely discontinued…
- Aclaris Therapeutics’ bosakitug fails Phase 2 eczema trial, TSLP program droppedAclaris Therapeutics announced that its experimental antibody bosakitug (ATI-045) did not meet the primary endpoint in a Phase 2 study for moderate-to-severe atopic dermatitis. The double‑blind Ad…